Coya Therapeutics to Participate at Upcoming September Investor Conferences
COYA(NASDAQ:COYA) HOUSTON, Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the...
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
COYAFDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON, Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a...
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
COYAHOUSTON, Aug. 12, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate...
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
COYAHOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas Summer Conference Date: June 24, 2025 Time: 10:30am ET (presentation) Webcast: https://www
HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target
COYACoya Therapeutics Announces Issuance Of U.S. Patent Relevant To Investigational RTU Liquid Formulation Of IL-2
COYAChardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
COYACoya Therapeutics Q1 EPS $(0.44) Misses $(0.20) Estimate, Sales $257.88K Miss $2.63M Estimate
COYAChardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
COYAD. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
COYACoya Therapeutics Announces Interim Results Of Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Treatment In Patients With Mild To Moderate Frontotemporal Dementia
COYAD. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
COYACoya Therapeutics Announces Publication of COYA 303 Combination Biologic Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Cell Death
COYAD. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
COYACoya Therapeutics Provides Status Update On Investigational Treg Exosome Platform For Neurodegenerative Diseases, Plans GMP Manufacturing And Large-Scale Clinical Batch Production In Q4 2025
COYAChardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
COYAD. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $18 Price Target
COYACoya Therapeutics FY 2024 GAAP EPS $(0.98) Beats $(1.09) Estimate, Sales $3.554M Miss $3.601M Estimate
COYAD. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target
COYACoya Therapeutics CEO To Discuss Alzheimer's Treatment Potential With GLP-1 Agonists In BTIG Webcast On Feb 27, 2025
COYACoya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive Funding To
COYACoya Therapeutics Appoints Arun Swaminathan, Ph.D., As CEO
COYACoya Therapeutics Completes Controlled Phase 2 Study Of Low Dose Interleukin-2 In Patients With Alzheimer's Disease
COYACoya Therapeutics Announces The Alzheimer's Drug Discovery Foundation Has Purchased 603,136 Shares Of Co.'s Stock At $8.29 Per Share
COYA